首页> 外国专利> New 1,3-disubstituted cycloheptene derivatives, are selective farnesyl transferase inhibitors useful for treating cancer diseases, restenosis or type I neurofibromatosis

New 1,3-disubstituted cycloheptene derivatives, are selective farnesyl transferase inhibitors useful for treating cancer diseases, restenosis or type I neurofibromatosis

机译:新的1,3-二取代的环庚烯衍生物是选择性的法呢基转移酶抑制剂,可用于治疗癌症,再狭窄或I型神经纤维瘤病

摘要

1,3-Disubstituted cycloheptene derivatives (I) are new. Cycloheptene derivatives of formula (I) and their enantiomers, diastereomers and acid or base addition salts are new. X = direct bond, alkylene, CO, S(O)n, S(O)n-A1, CO-A1, A1-S(O)n-A1 or A1-CO-A1 (bonded to the ring at the left-hand terminal); A1 = alkylene; n = 0-2; Y = aryl, heteroaryl, cycloalkyl or heterocycloalkyl (all optionally substituted (os) by R8); R1 - R4 = H or as for Y; or pairs of adjacent groups R1 - R4 may together form bonds; or R1 + R2, R2 + R3 or R3 + R4 = group completing a fused benzene ring or fused 5- or 6-membered aromatic or partially aromatic heterocycle containing 1 or 2 of N, O and S as heteroatom(s); T = CHR5, NR5 or NR5CO (bonded to the ring at the left-hand terminal); R5 = H; or alkyl, aryl, heteroaryl, aralkyl or heteroaralkyl (all os by one or more R7); V = H; or aryl or heteroaryl (both os by one or more R7); A2 = -(CR6R'6)p; p = 0-4 (but not 0 if T = NR5); R6, R'6 = H, alkyl (os by R9), alkenyl, alkynyl or R9; R9 = OR5, NR5R'5, S(O)nR5, CONR5R'5, NR5COR'5, NR5SO2R'5, SO2NR5R'5 or NR5COOR'5; R'5 = as R5; R7 = halo, alkyl, alkoxy, OH, SH, alkylthio, CN, NH2 (os by 1 or 2 alkyl), NO2, COOH, alkoxycarbonyl, CONH2 (os by 1 or 2 alkyl), carbamoyl, os aryl, os aralkyl, os heteroaryl, os heteroaralkyl, os cycloalkyl, os cycloalkylalkyl, os heterocycloalkyl or os heterocycloalkylalkyl; R8 = halo, =O, OH, CN, NO2, COOH, alkoxycarbonyl, U-R80 or A80-U-R80; A80 = alkylene; U = direct bond, O, NH, S(O)n, NHCO, CONH, SO2NH or NHSO2; R80 = alkyl, aryl, aralkyl, heteroaryl or heteroarylalkyl; alkyl or alkylene moieties have 1-6C; cycloalkyl moieties have 3-8C; heterocycloalkyl moieties are 5-7 membered and contain 1-3 of N, O and S as heteroatom(s); aryl moieties are phenyl or naphthyl; heteroaryl moieties are mono- or bicyclic 5-11 membered systems containing at least one aromatic ring and 1-5 of N, O and S as heteroatom(s); the substituents in os aryl, heteroaryl, aralkyl or heteroaralkyl are one or more of CN, alkylcarbonyl, CONH2 (os by 1 or 2 alkyl) or halo (in the ring part); the substituents in os cycloalkyl, heterocycloalkyl, cycloalkylalkyl or heterocycloalkylalkyl are one or more of =O, CN, alkylcarbonyl, CONH2 (os by 1 or 2 alkyl) or halo (in the ring part). An Independent claim is included for the preparation of (I).
机译:1,3-二取代的环庚烯衍生物(I)是新的。式(I)的环庚烯衍生物及其对映异构体,非对映异构体和酸或碱加成盐是新的。 X =直接键,亚烷基,CO,S(O)n,S(O)n-A1,CO-A1,A1-S(O)n-A1或A1-CO-A1(键在左侧的环上-手终端); A1 =亚烷基; n = 0-2; Y =芳基,杂芳基,环烷基或杂环烷基(所有被R8任选取代的(os)); R1-R4 = H或与Y相同;或成对的相邻基团R1-R4可以一起形成键;或R 1 + R 2,R 2 + R 3或R 3 + R 4 =完成稠合苯环或稠合5或6元芳族或部分芳族杂环的基团,其含有1或2个N,O和S作为杂原子;或T = CHR5,NR5或NR5CO(结合在左侧端子的环上); R5 = H;或烷基,芳基,杂芳基,芳烷基或杂芳烷基(全部为一个或多个R 7的os);或V = H;或芳基或杂芳基(两者均为一个或多个R 7所取代); A2 =-(CR6R'6)p; p = 0-4(但如果T = NR5,则不为0); R6,R'6 = H,烷基(R9上的os),烯基,炔基或R9; R9 = OR5,NR5R'5,S(O)nR5,CONR5R'5,NR5COR'5,NR5SO2R'5,SO2NR5R'5或NR5COOR'5; R'5 =与R5相同; R7 =卤素,烷基,烷氧基,OH,SH,烷硫基,CN,NH2(以1或2个烷基为邻),NO2,COOH,烷氧羰基,CONH2(以1或2个烷基为邻),氨基甲酰基,芳基,芳烷基, os杂芳基,os杂芳烷基,os环烷基,os环烷基烷基,os杂环烷基或os杂环烷基烷基; R8 =卤素,= O,OH,CN,NO2,COOH,烷氧羰基,U-R80或A80-U-R80; A80 =亚烷基; U =直接键,O,NH,S(O)n,NHCO,CONH,SO2NH或NHSO2; R80 =烷基,芳基,芳烷基,杂芳基或杂芳基烷基;烷基或亚烷基部分具有1-6C;环烷基部分具有3-8C;杂环烷基部分为5-7元且含有1-3个N,O和S作为杂原子;芳基部分是苯基或萘基;杂芳基部分是包含至少一个芳环和1-5个N,O和S作为杂原子的单环或双环5-11元系统;芳基,杂芳基,芳烷基或杂芳烷基中的取代基是CN,烷基羰基,CONH 2(在1或2个烷基上的取代基)或卤素(在环部分中)中的一个或多个;环烷基,杂环烷基,环烷基烷基或杂环烷基烷基中的取代基为= O,CN,烷基羰基,CONH 2(为1或2个烷基取代)或卤素(在环部分中)中的一个或多个。准备(I)包括独立权利要求。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号